Latest News on CLB

Financial News Based On Company


Advertisement
Advertisement

An investment adviser reports more than 5% ownership of Core Laboratories (CLB).

https://www.stocktitan.net/sec-filings/CLB/schedule-13g-a-core-laboratories-inc-de-amended-passive-investment-di-28cdfe0a76aa.html
EARNEST Partners, LLC has filed an amended ownership report for Core Laboratories Inc. (CLB), disclosing a beneficial ownership of 2,629,631 common shares, representing 5.7% of the class as of September 30, 2026. The investment adviser reported sole voting power over 1,805,630 shares and shared voting power over 165,171 shares. This filing indicates that no single client interest held by EARNEST Partners relates to more than 5% of CLB's class.

Did Core Laboratories' Fall Catch You Out? What Investors Missed

https://sg.finance.yahoo.com/news/did-core-laboratories-fall-catch-231911771.html
Core Laboratories (CLB) reported a significant drop in net income and net margin in Q3 2026, catching many investors off guard, with shares down 46.5% year-to-date. This decline contradicted both bullish and bearish forecasts, which had assumed higher profitability. Despite the recent performance, Simply Wall St's Narrative still sees Core Laboratories' Fair Value above its current price of US$9.03, based on its expansion into international and offshore projects and high-value diagnostic services.

CLB Q3 Earnings Miss Estimates on Higher Costs and Disruptions

https://www.tradingview.com/news/zacks:1f0fb6858094b:0-clb-q3-earnings-miss-estimates-on-higher-costs-and-disruptions/
Core Laboratories Inc. (CLB) reported Q3 2026 adjusted earnings of 16 cents per share, missing estimates, while revenues of $132.1 million slightly beat expectations. The company faced challenges from geopolitical disruptions and higher operating costs, particularly in its Reservoir Description segment, though Production Enhancement showed growth. Despite sequential improvements in operating margins and positive free cash flow, management anticipates continued disruptions in Q4, projecting revenues between $128.5 million and $134.5 million.

Core Laboratories N.V. (CLB) Seasonal returns chart

https://uk.finance.yahoo.com/quote/CLB/seasonality/
This article provides a brief overview of Core Laboratories N.V. (CLB), focusing on its stock performance and historical seasonality. It highlights the current stock price, recent dividend announcement, and a chart displaying average monthly price returns from 2016 to 2026. The information is presented within the context of market data from Yahoo Finance.

Weekly Recap: Revenue growth and Reservoir Description margin gain

https://www.tradingview.com/news/tradingview:106e5c897cbef:0-weekly-recap-revenue-growth-and-reservoir-description-margin-gain/
Core Laboratories Inc. (CLB) reported a 6% sequential revenue increase, driven by a rebound in product sales and a 7% rise in Reservoir Description revenue, which also saw its operating margin double to 10%. Despite geopolitical headwinds, the company generated $5 million in operating cash flow, continued its dividend, repurchased shares, and secured new projects in Malaysia and the Black Sea.
Advertisement

Core Laboratories Inc. (NYSE:CLB) Shareholders to Get $0.01 Quarterly Dividend

https://www.marketbeat.com/instant-alerts/dividend-core-laboratories-inc-nyse-clb-shareholders-to-get-001-quarterly-dividend-2026-10-29/
Core Laboratories Inc. (NYSE:CLB) has declared a quarterly dividend of $0.01 per share, to be paid on November 30 to shareholders of record on November 9. This represents an annualized dividend of $0.04, offering a 0.4% yield, and is well-covered by earnings with a payout ratio of 4.7%. The company recently reported quarterly EPS of $0.16, matching estimates, and revenue of $132.08 million, which slightly exceeded expectations despite a slight year-over-year decline.

Core Laboratories Inc. (CLB) Posts Q3 Revenue $132.1M, EPS $0.12; Guides Q4 Flat

https://www.tradingview.com/news/tradingview:75f8a41c41cb5:0-core-laboratories-inc-clb-posts-q3-revenue-132-1m-eps-0-12-guides-q4-flat/
Core Laboratories Inc. (CLB) reported Q3 2026 revenue of $132.1 million and GAAP EPS of $0.12, with an ex-items EPS of $0.16. The company provided Q4 revenue guidance of $128.5 million to $134.5 million and EPS guidance of $0.12 to $0.20, indicating a flat sequential outlook due to Middle East disruptions. International demand drove sequential growth in reservoir description, while U.S. product sales led production enhancement.

Revenue rose 6% sequentially at Core Laboratories (CLB), but Q3 EPS fell year over year.

https://www.stocktitan.net/sec-filings/CLB/8-k-core-laboratories-inc-de-reports-material-event-bdb8d0e94320.html
Core Laboratories Inc. (CLB) reported third-quarter 2026 revenue of $132.077 million, a 6.0% sequential increase but a 1.8% year-over-year decrease. Diluted EPS attributable to Core fell 60.0% year over year to $0.12. For the fourth quarter, the company projects revenue between $128.5 million and $134.5 million, with diluted EPS expected to range from $0.12 to $0.20.

Core Laboratories Inc. Estimates – NYSE:CLB

https://www.tradingview.com/symbols/NYSE-CLB/financials-estimates/
This article provides access to financial actuals and analyst estimates for Core Laboratories Inc. (NYSE: CLB) on TradingView. Users can explore reported financial data and compare it with average, high, and low estimates across various financial statements and valuation metrics. The platform also allows visualization of trends over time for the company.

Form 4 Core Laboratories NV For: 5 October By Investing.com

https://uk.investing.com/news/stock-market-news/form-4-core-laboratories-nv-for-5-october-93CH-4895870
This article reports on a Form 4 filing for Core Laboratories NV (CLB) on October 5, 2026. The filing indicates insider trading activity for the company, which is a common disclosure for publicly traded entities. The brief notice provides the date of the filing and the company ticker, but no further details about the specific transactions.
Advertisement

Form 4 Core Laboratories NV For: 5 October

https://in.investing.com/news/stock-market-news/form-4-core-laboratories-nv-for-5-october-93CH-5619032
This article announces the Form 4 filing for Core Laboratories NV for October 5th. It is a brief, standard notification of a regulatory filing, without additional details or analysis in the provided content. The filing is related to the company CLB.

Form 4 Core Laboratories NV For: 5 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-core-laboratories-nv-for-5-october-93CH-4866356
This article reports on a Form 4 filing for Core Laboratories NV (CLB) on October 5, 2026. The brief notice confirms the filing, with Core Laboratories NV's stock symbol and a slight positive performance indicated. The rest of the content includes market data, news headlines, and navigational elements from Investing.com.

CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL

https://finance.yahoo.com/markets/stocks/articles/core-laboratories-announces-timing-third-201500285.html
Core Laboratories (NYSE: "CLB") will host its third quarter 2026 earnings conference call on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT. An earnings press release will precede the call on October 28, 2026, accessible via the company's website. The call will feature Larry Bruno (Chairman and CEO), Chris Hill (CFO), and Gwen Gresham (SVP Corporate Development and Investor Relations) to discuss financial and operational results.

Core Laboratories sets Oct 29 call for Q3FY26 results

https://scanx.trade/stock-market-news/companies/core-laboratories-sets-oct-29-call-q3fy26-results/52431831
Core Laboratories (NYSE: CLB) has scheduled its Q3 FY2026 earnings conference call for October 29, 2026, with the press release expected after market close on October 28, 2026. Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will lead the discussion at 7:30 am CDT / 8:30 am EDT. Stakeholders can access materials and the live webcast via the company's investor relations website.

CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL

https://www.moomoo.com/news/post/1000525914/core-laboratories-announces-timing-of-third-quarter-2026-earnings-release
Core Laboratories (NYSE: "CLB") announced it will release its third-quarter 2026 financial results on October 25, 2026, after the market closes. The company will then host a conference call on October 26, 2026, at 8:30 a.m. CT to discuss these results. Interested parties can access the call via webcast or dial-in.
Advertisement

After the Oct. 28 close, Core Laboratories will release its results; a webcast follows next morning.

https://www.stocktitan.net/news/CLB/core-laboratories-announces-timing-of-third-quarter-2026-earnings-xyyw4glnm7a5.html
Core Laboratories (NYSE: CLB) announced that it will release its third-quarter 2026 earnings after market close on October 28, 2026. A conference call for investors and analysts will follow on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT, featuring CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham. The earnings press release and a replay/transcript of the call will be available on the company's website.

CORE LABORATORIES ANNOUNCES TIMING OF THIRD QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL

https://www.tradingview.com/news/prnewswire:582d315ee7980:0-core-laboratories-announces-timing-of-third-quarter-2026-earnings-release-and-conference-call/
Core Laboratories (NYSE: "CLB") will host its third quarter 2026 earnings conference call for investors and analysts on October 29, 2026, at 7:30 a.m. CDT / 8:30 a.m. EDT. An earnings press release will precede the call on October 28, 2026, accessible via the Company's website. The call will feature discussions on financial and operational results by Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Corporate Development and Investor Relations Gwen Gresham.

CLB Declines 35% in the Past Six Months: How to Play the Stock?

https://es.tradingview.com/news/zacks:4f94331a2094b:0-clb-declines-35-in-the-past-six-months-how-to-play-the-stock/
Core Laboratories Inc. (CLB) shares have declined significantly over the past six months, underperforming its sector and peers due to internal challenges and geopolitical headwinds. While the company faces risks from its exposure to international conflicts and declining 2026 earnings estimates, its Production Enhancement segment, proprietary technologies, and potential rebound in international offshore activity offer long-term upside. The article suggests a "Hold" rating, recommending patience due to near-term pressures.

CLB Declines 35% in the Past Six Months: How to Play the Stock?

https://www.tradingview.com/news/zacks:4f94331a2094b:0-clb-declines-35-in-the-past-six-months-how-to-play-the-stock/
Core Laboratories (CLB) has significantly underperformed the oil and energy sector, declining 35.1% over the past six months, despite some positive developments in its Production Enhancement segment and potential for international offshore activity recovery. While proprietary technologies and an asset-light model offer long-term upside, the company faces challenges including geopolitical exposure in its Reservoir Description segment, weakened cash flow generation, and declining 2026 earnings estimates. The article concludes with a "Hold" rating, suggesting patience due to near-term pressures.

Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline

https://www.easternprogress.com/earnings-preview-core-laboratories-clb-q2-earnings-expected-to-decline/article_e93b5e64-7197-58f2-887d-ce42c2826b68.html
Core Laboratories (CLB) is anticipated to report a year-over-year decline in earnings and revenues for Q2 2026, with an expected EPS of $0.08 and revenues of $127.56 million. Despite a Zacks Rank of #4 (Sell), the company shows a positive Earnings ESP of +6.67%, suggesting a potential earnings beat, though this is not a strong indicator for negative-ranked stocks. Investors are advised to consider other factors beyond the earnings surprise history for this particular stock.
Advertisement

Zacks Research Cuts Earnings Estimates for Core Laboratories

https://www.marketbeat.com/instant-alerts/estimates-zacks-research-cuts-earnings-estimates-for-core-laboratories-2026-09-16/
Zacks Research has reduced its FY2026 EPS estimate for Core Laboratories (NYSE:CLB) to $0.61 from $0.62, although this is still above the $0.56 consensus. While the company beat Q2 earnings expectations with $0.11 EPS, revenue declined 4.3% year over year. Despite the lowered near-term estimates, analysts maintain a "Moderate Buy" rating with a $21 target price, and insider buying and high institutional ownership reflect continued confidence.

Zacks Research Expects Weaker Earnings for Core Laboratories

https://www.marketbeat.com/instant-alerts/estimates-zacks-research-expects-weaker-earnings-for-core-laboratories-2026-09-15/
Zacks Research has lowered its Q3 2026 EPS forecast for Core Laboratories to $0.17, with full-year earnings projected at $0.56 per share. Despite beating EPS expectations in its last quarterly report, revenue decreased by 4.3% year-over-year. The stock has a "Moderate Buy" consensus rating and a $21 average price target, though it was trading down 2.3% at $12.21, significantly below its 52-week high.

Legal & General Group Plc Buys Shares of 122,575 Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-buys-shares-of-122575-core-laboratories-inc-clb-2026-09-07/
Legal & General Group Plc recently acquired 122,575 shares of Core Laboratories Inc. (NYSE:CLB) for approximately $1.43 million, establishing a 0.27% stake in the company. Institutional ownership of Core Laboratories now stands at 97.81%. The purchase follows positive analyst sentiment, with several upgrades to "hold" or "buy" ratings and a consensus "Moderate Buy" rating with a target price of $21.00.

Core Laboratories NV (CLB) Shareholding Pattern – Promoters, FIIs & DIIs

https://www.valueresearchonline.com/stocks/45974/core-laboratories-nv-clb/shareholding/
This article details the shareholding pattern of Core Laboratories NV (CLB), an Oil & Gas Equipment company, as of September 25, 2026. It provides a comprehensive list of institutional shareholders holding more than 1% of equity, their percentage holdings, changes in shares, and filing dates dating back to December 2021. The report also includes recent insider trading activities, showing individual buy and sell transactions with dates, share numbers, prices, and values.

Bank of New York Mellon Corp Makes New Investment in Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-makes-new-investment-in-core-laboratories-inc-clb-2026-09-06/
Bank of New York Mellon Corp has acquired a new position in Core Laboratories Inc. (NYSE:CLB), purchasing 401,283 shares valued at approximately $4.7 million, representing about 0.87% of the company. Institutional investors now own 97.81% of CLB, and the stock received an upgrade from Johnson Rice to "buy" with a $21 price target, contributing to a "Moderate Buy" consensus rating. Despite a slight revenue decline, Core Laboratories exceeded quarterly earnings expectations, reporting $0.11 EPS against a $0.09 consensus.
Advertisement

Zacks Industry Outlook Highlights TechnipFMC, Oceaneering International, Inc. and Core Laboratories

https://finance.yahoo.com/energy/articles/zacks-industry-outlook-highlights-technipfmc-124200633.html
The Zacks Oil and Gas-Field Services industry faces challenges such as high debt exposure and lower upstream spending, despite outperforming the S&P 500 and the broader Oil-Energy sector. Zacks highlights TechnipFMC, Oceaneering International, Inc., and Core Laboratories as companies poised to navigate these difficulties. Oceaneering International and TechnipFMC boast strong backlogs, while Core Laboratories focuses on maximizing invested capital.

BlackRock Inc. Makes New Investment in Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-blackrock-inc-makes-new-investment-in-core-laboratories-inc-clb-2026-08-30/
BlackRock Inc. has made a new investment in Core Laboratories Inc. (NYSE:CLB), acquiring over 7.46 million shares valued at approximately $86.9 million, giving them a 16.26% stake. Other institutional investors have also adjusted their positions, and insider activity shows CEO Lawrence Bruno increasing his ownership. The company reported beating quarterly EPS expectations but saw a 4.3% year-over-year revenue decline, with analysts maintaining a "Moderate Buy" rating and a $21 price target.

Bank of America Corp DE Has $3.77 Million Position in Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-377-million-position-in-core-laboratories-inc-clb-2026-08-30/
Bank of America Corp DE significantly increased its stake in Core Laboratories Inc. (NYSE:CLB) by 59.6% in the first quarter, now holding 224,618 shares valued at $3.77 million. This comes as Core Laboratories reported beating quarterly EPS estimates but saw a revenue decline. The company also announced a quarterly dividend and received an analyst upgrade to "buy" from Johnson Rice, contributing to a "Moderate Buy" consensus rating.

Avoiding Lag: Real-Time Signals in (CLB) Movement

https://news.stocktradersdaily.com/news_release/21/Avoiding_Lag:_Real-Time_Signals_in_CLB_Movement_083026051201_1788124321.html
This article analyzes Core Laboratories Inc. (CLB) using AI models to provide real-time trading signals and strategies. It highlights mixed sentiment, an oscillation pattern, and a significant risk-reward short setup, offering detailed entry, target, and stop-loss levels for various trading approaches. The analysis includes multi-timeframe signal assessments for near-term, mid-term, and long-term horizons, along with support and resistance levels.

Core Laboratories (CLB) Up 18.7% Since Last Earnings Report: Can It Continue?

https://finance.yahoo.com/markets/stocks/articles/core-laboratories-clb-18-7-153005943.html
Core Laboratories (CLB) has seen its shares jump 18.7% since its last earnings report, outperforming the S&P 500. The company reported mixed Q2 2026 results, beating earnings estimates due to its Production Enhancement segment but missing revenue expectations, primarily impacted by geopolitical conflicts. Looking ahead, CLB anticipates sequential revenue growth in Q3, driven by improving activity in South Atlantic Margin and Asia-Pacific, alongside continued technological advancements.
Advertisement

Kwaku Temeng to Resign from Core Laboratories Board, Effective Oct 1, 2026

https://www.tradingview.com/news/tradingview:a24d45bf6cdc5:0-kwaku-temeng-to-resign-from-core-laboratories-board-effective-oct-1-2026/
Kwaku Temeng is set to resign from the Core Laboratories (CLB) board of directors, effective October 1, 2026. His resignation stems from disagreements with the board regarding strategic direction and certain governance practices. Temeng has served on the board for over five years, holding roles as Chairman of the Nominating Committee and a member of the Compensation Committee.

Core Laboratories (NYSE: CLB) director resigns over strategy dispute

https://www.stocktitan.net/sec-filings/CLB/8-k-core-laboratories-inc-de-reports-material-event-9573035bcb38.html
Core Laboratories (NYSE: CLB) director Kwaku Temeng is resigning from the Board, effective October 1, 2026, due to disagreements over the company's strategic direction and governance practices, including succession planning and research priorities. Temeng, who chaired the Nominating Committee and served on the Compensation Committee, verbally notified the Board on August 19, 2026, and confirmed his resignation by letter on August 25, 2026. The company acknowledged his five years of service while noting the internal board differences.

Core Laboratories Inc. Announces Resignation of Kwaku Temeng as Director, Chairman of the Nominating Committee and as A Member of the Compensation Committee, Effective October 1, 2026

https://www.marketscreener.com/news/core-laboratories-inc-announces-resignation-of-kwaku-temeng-as-director-chairman-of-the-nominating-ce7858d9d889f72d
Core Laboratories Inc. announced the resignation of Kwaku Temeng from its Board of Directors, effective October 1, 2026. Mr. Temeng, who also chaired the Nominating Committee and served on the Compensation Committee, cited disagreements with the Board regarding the company's strategic direction and governance practices, specifically concerning succession planning and research priorities. The Board stated that his primary disagreement revolved around succession planning, a process supported by the majority of directors.

Core Laboratories Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/core-laboratories/employees
Core Laboratories, Inc. (CLB) had approximately 3,318 employees worldwide as of March 2026, representing a 1.0% increase from the previous year. The company's workforce is concentrated in North America (32.8%), with an average salary of $52,895. Core Laboratories is actively hiring, with 96 active job postings in 2026, despite a negative and declining employee sentiment.

Heartland Advisors Inc. Buys Shares of 1,058,311 Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-heartland-advisors-inc-buys-shares-of-1058311-core-laboratories-inc-clb-2026-08-22/
Heartland Advisors Inc. has acquired a significant new position in Core Laboratories Inc. (NYSE:CLB), purchasing 1,058,311 shares valued at approximately $12.3 million, representing a 2.31% stake in the company. This move comes as institutional investors now hold 97.81% of Core Laboratories' stock, and analysts have recently upgraded their ratings, setting a consensus "Moderate Buy" with a $21 target price. Despite a year-over-year revenue decline, the company surpassed quarterly EPS estimates and declared a $0.01 dividend.
Advertisement

Advisors Capital Management LLC Makes New $2.77 Million Investment in Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-advisors-capital-management-llc-makes-new-277-million-investment-in-core-laboratories-inc-clb-2026-08-22/
Advisors Capital Management LLC has made a new investment of $2.77 million in Core Laboratories Inc. (NYSE:CLB), acquiring 237,398 shares during the second quarter. This move makes Advisors Capital Management LLC a significant institutional holder, owning 0.52% of the oil and gas company. Other institutional investors also adjusted their positions in Core Laboratories, which recently reported earnings that beat analyst estimates and declared a quarterly dividend.

Q4 EPS Forecast for Core Laboratories Lifted by Analyst

https://www.marketbeat.com/instant-alerts/q4-eps-forecast-for-core-laboratories-lifted-by-analyst-2026-08-21/
Zacks Research has increased its Q4 2027 EPS forecast for Core Laboratories (NYSE:CLB) to $0.24, up from $0.23, and projected Q1 2028 EPS at $0.11. This positive revision follows Core Laboratories' recent quarterly earnings report, which saw the company beat EPS expectations ($0.11 vs. $0.09 consensus) despite a 4.3% year-over-year revenue decline. Analyst sentiment for CLB has shifted to a "Moderate Buy," with an average price target of $21.00, significantly higher than its recent opening price of $12.29, and insider buying by CEO Lawrence Bruno further underscores confidence in the stock.

101,648 Shares in Core Laboratories Inc. $CLB Purchased by Rice Hall James & Associates LLC

https://www.marketbeat.com/instant-alerts/filing-101648-shares-in-core-laboratories-inc-clb-purchased-by-rice-hall-james-associates-llc-2026-08-19/
Rice Hall James & Associates LLC recently purchased 101,648 shares of Core Laboratories Inc. (NYSE:CLB), valued at approximately $1.18 million, representing 0.22% of the company. Core Laboratories reported Q2 EPS of $0.11, beating estimates, but revenue missed expectations, while institutional investors now own 97.81% of the company. Analysts currently have a "Moderate Buy" rating for CLB with a $21 target price, significantly higher than its recent trading price of $12.45.

Renaissance Technologies LLC Sells 132,797 Shares of Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-sells-132797-shares-of-core-laboratories-inc-clb-2026-08-16/
Renaissance Technologies LLC significantly reduced its stake in Core Laboratories Inc. by 72.4% in Q1 2026, selling 132,797 shares. Despite this institutional sell-off, Core Laboratories reported exceeding Q1 EPS expectations, and CEO Lawrence Bruno increased his personal holdings in the company. Analyst sentiment for Core Laboratories has also improved, with an upgrade to "buy" and a consensus target price of $21.00.

Disciplined Growth Investors (CLB) reports 6.6% Core Laboratories stake on Schedule 13G/A

https://www.stocktitan.net/sec-filings/CLB/schedule-13g-a-core-laboratories-inc-de-amended-passive-investment-di-6a4352d382b5.html
Disciplined Growth Investors, Inc. has reported a 6.6% beneficial ownership stake in Core Laboratories Inc. (CLB) through a Schedule 13G/A filing. The firm beneficially owns 3,042,177 common shares, holding sole voting power over 2,961,959 shares and sole dispositive power over all 3,042,177 shares. This indicates a significant institutional investment with controlled voting and dispositive rights.
Advertisement

Ariel Investments (CLB) discloses 30.5% Core Laboratories stake in Schedule 13G/A

https://www.stocktitan.net/sec-filings/CLB/schedule-13g-a-core-laboratories-inc-de-amended-passive-investment-di-667246891c1f.html
Ariel Investments, LLC has disclosed a significant stake in Core Laboratories Inc. common stock through a Schedule 13G/A filing. The investment firm beneficially owns 14,074,945 shares, which accounts for 30.5% of the outstanding common stock as of June 30, 2026. This includes sole voting power over 13,141,081 shares and sole dispositive power over all 14,074,945 shares, with Ariel Fund specifically holding 6,474,663 shares.

Core Laboratories (NYSE:CLB) Stock Rating Upgraded by Johnson Rice

https://www.marketbeat.com/instant-alerts/core-laboratories-nyseclb-stock-rating-upgraded-by-johnson-rice-2026-08-13/
Johnson Rice upgraded Core Laboratories (NYSE:CLB) from a "hold" to a "buy" rating, setting a $21.00 price target. This upgrade implies a significant upside, although the broader analyst consensus remains "Hold." The company recently reported better-than-expected EPS but missed revenue estimates, while its CEO and institutional investors have shown confidence through stock purchases and substantial ownership.

Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture

https://www.webull.com/news/15361143144539136
Core Laboratories (NYSE:CLB) recently reported weak earnings, which did not significantly impact its stock price. An analysis suggests that the company's profit was boosted by US$7.1 million in unusual items in the last year, raising concerns that future profits may be weaker without these non-recurring contributions. Investors are cautioned to look beyond the statutory earnings and consider underlying weaknesses, as well as risks facing the company.

Core Laboratories (CLB) Q2 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/stocks/CLB-N/pressreleases/3730601/core-laboratories-clb-q2-2026-earnings-call-transcript/
Core Laboratories (CLB) reported Q2 2026 earnings, showing 2% sequential revenue growth driven by increased demand for completion products, despite ongoing geopolitical conflicts in the Middle East and Russia/Ukraine impacting its Reservoir Description segment. The company highlighted improved Production Enhancement operating margins due to higher product sales and resolved tax matters, while also maintaining a commitment to shareholder returns through dividends and share repurchases. Core Labs provided Q3 2026 guidance projecting continued sequential revenue growth, primarily from international markets outside the conflict zones.

Core Laboratories N.V. (CLB) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/CLB/
This Yahoo Finance page provides comprehensive financial data for Core Laboratories N.V. (CLB), including its current stock price, dividend information, key statistics, historical data, and analyst insights. It details the company's business segments—Reservoir Description and Production Enhancement—which serve the oil and gas industry, and offers performance comparisons against the S&P 500. The page also presents earnings trends, valuation measures, and a list of comparable companies in the Oil & Gas Equipment & Services sector.
Advertisement

Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture

https://simplywall.st/stocks/us/energy/nyse-clb/core-laboratories/news/core-laboratories-nyseclb-weak-earnings-may-only-reveal-a-pa
Core Laboratories' recent earnings report, despite weak numbers, did not cause significant stock movement. The analysis suggests that the company's profit was boosted by US$7.1m in unusual items, implying that statutory profits might be better than its underlying earnings power. Investors are advised to consider these underlying weaknesses and other factors like margins, growth forecasts, and return on investment.

Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture

https://simplywall.st/stocks/us/energy/nyse-clb/core-laboratories/news/core-laboratories-nyseclb-weak-earnings-may-only-reveal-a-pa/amp
Core Laboratories Inc.'s recent weak earnings report did not significantly impact its stock movement, but an analysis suggests underlying weaknesses beyond soft profit numbers. The company's profit was boosted by US$7.1 million in unusual items, which are typically not repeated, potentially leading to weaker profits next year. Investors are advised to consider these factors when evaluating the company's true earnings power.

Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates

https://www.tradingkey.com/markets/stocks/clb/forecast
This article provides an earnings forecast for Core Laboratories Inc (CLB), noting its current earnings forecast score of 6.00 and an average price target of $14.00 based on three analysts. It highlights an expected revenue of $131.33M for the next quarter and an anticipated EPS of $0.15. The analyst consensus is a "Hold" rating for the stock.

Dimensional Fund Advisors LP Increases Stock Position in Core Laboratories Inc. $CLB

https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-increases-stock-position-in-core-laboratories-inc-clb-2026-08-07/
Dimensional Fund Advisors LP has increased its stake in Core Laboratories Inc. (NYSE:CLB) by 10.0% in the first quarter, now owning 1,352,329 shares valued at $22,705,000. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., American Century Companies Inc., and Quantbot Technologies LP have also adjusted their positions in the oil and gas company. The article also details Core Laboratories' recent financial performance, dividend announcement, insider buying activity by CEO Lawrence Bruno, and current analyst ratings.

Core Laboratories Inc. (CLB) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/CLB/
This article provides a comprehensive overview of Core Laboratories Inc. (CLB), including its current stock price, recent news like its dividend announcement, and detailed financial data. It covers company performance metrics, analyst ratings, and an in-depth profile of its operations in the oil and gas equipment and services sector. The information aims to offer potential investors a clear picture of CLB's market position and financial health.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement